• tech2b
  • tech2b
  • News
  • News Detailseite
  • Cytonus, the US-based Biotech Platform Company, gains a boost from Strategic Partnership with Europe-based Phoenestra

Cytonus, the US-based Biotech Platform Company, gains a boost from Strategic Partnership with Europe-based Phoenestra

[Quelle: CISION PRWeb]

Cytonus and Phoenestra announce plans to accelerate and expand their combined IP assets

With numerous products in its pipeline, Cytonus Therapeutics Inc. today announced a strategic partnership agreement with Phoenestra GmbH to accelerate Cytonus’ existing products and to expand the companies’ intellectual property assets. Cytonus is a biotech company founded in San Diego, California. Phoenestra is a biotech company located in Austria.

Phoenestra has developed IP assets in connection with cell reprogramming as well as non-invasive sources for cell lines. The strategic partnership with Cytonus will expand both companies’ combined IP assets through co-development collaboration projects. As part of the strategic partnership, Phoenestra will also provide Cytonus new manufacturing capabilities, including a new production facility focused on operating in full compliance with Good Manufacturing Practices (GMP). Since its inception, Phoenestra has focused on an end-to-end approach to ensure both quality control and scalability, starting with the efficient sourcing of material from unique cell sources and producing finished GMP-certified products.

“We are honored to join forces with Cytonus,” commented Phoenestra CEO and Founder Klaus Graumann, PhD. “Phoenestra will work to complement and accelerate Cytonus’ game-changing Cargocyte™ biotechnologies.”

“Our co-development projects will create fertile ground for further expanding the combined IP assets and pipeline of products for Cytonus and Phoenestra,” commented Phoenestra CFO and Founder Otto Kanzler.

“Cytonus is thrilled to gain the benefit of Phoenestra’s scientific excellence, quality IP assets, as well as the top talent of their highly experienced executives, who have decades of biopharma industry experience and were instrumental in the past development of more than eleven biologics that are now commercial products,” commented Cytonus’ Founder and CEO Remo Moomiaie-Qajar, MD.

About Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a US-based biotech platform company that is developing proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers and inflammatory diseases, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation molecular delivery devices, which have numerous medical applications across unmet therapeutic areas. Cargocytes are engineered to transport a multiplicity of therapeutic payloads into targeted tissues, and can be programmed to deliver selective, potent, and controllable “off-the-shelf” therapies. Cytonus’ vast platform of products has the potential to improve the health and lives of millions of people across the globe.

www.cytonus.com

www.phoenestra.com

<< zurück